Adverse Events following Immunization (AEFI) with the Novel Influenza A (H1N1) 2009 Vaccine: Findings from the National Registry of All Vaccine Recipients and AEFI and the Passive Surveillance System in South Korea

被引:0
|
作者
Kim, Jong-Hee [2 ,5 ]
Cho, Hee-Yeon [3 ]
Hennessey, Karen A. [6 ]
Lee, Hoan Jong [4 ]
Bae, Geun Ryang [2 ]
Kim, Hyeon Chang [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Prevent Med, Seoul 120752, South Korea
[2] Korea Ctr Dis Control & Prevent, Div VPD Control & NIP, Chungchungbuk Do, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea
[5] Yonsei Univ, Grad Sch, Dept Publ Hlth, Seoul 120752, South Korea
[6] WHO, Western Pacific Reg Off, Div Expanded Program Immunizat, Manila, Philippines
关键词
GUILLAIN-BARRE-SYNDROME; MONOVALENT VACCINES; REPORTING SYSTEM; UNITED-STATES; SAFETY; TRIAL; AGE;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study characterized the adverse events following immunization (AEFI) with the novel influenza A (H1N1) 2009 vaccine in Korea. Data on immunization and AEFI were collected between October 27, 2009 and March 15, 2010 through the national immunization registry and passive surveillance systems. The frequency of AEFI and serious adverse events (SAEs) were calculated according to age, sex, priority group, and vaccine type. In 13,758,527 vaccine recipients aged 6 months or older, 2,530 AEFI were reported (18.4 per 100,000 immunizations). The AEFI reporting rate was highest among people aged 10-19 years (29.6 per 100,000 immunizations) and was higher in female recipients than in male recipients (20.0 versus 16.7 per 100,000 immunizations). Most AEFIs were nonspecific systematic reactions that occurred within 24 h (77.4%) after vaccine administration. A total of 178 vaccine-related SAEs were identified, and vaccine-related mortalities were not reported. This study showed that the AEFI reporting rate after influenza A (H1N1) 2009 vaccinations was relatively high, especially in the younger population. Mild systemic reactions accounted for the majority of reported AEFI, and fatal SAEs were rare. This study also implied that passive surveillance might be an efficient safety monitoring system that can detect relatively rare AEFI.
引用
收藏
页码:99 / 104
页数:6
相关论文
共 29 条
  • [21] Unusual Patterns of IgG Avidity in Some Young Children following Two Doses of the Adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine
    Yam, Karen K.
    Gupta, Jyotsana
    Brewer, Angela
    Scheifele, David W.
    Halperin, Scott
    Ward, Brian J.
    CLINICAL AND VACCINE IMMUNOLOGY, 2013, 20 (04) : 459 - 467
  • [22] Higher Immunological Protection of Pandemic 2009 H1N1 Influenza Live Virus Infection than Split Vaccine Against the Homologous Virus for Long Term Immunization in Ferret
    Zhan, Lingjun
    Deng, Wei
    Bao, Linlin
    Lv, Qi
    Ma, Chunmei
    Li, Fengdi
    Xu, Lili
    Qin, Chuan
    INDIAN JOURNAL OF VIROLOGY, 2012, 23 (03): : 270 - 277
  • [23] A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection
    Honda-Okubo, Yoshikazu
    Kolpe, Annasaheb
    Li, Lei
    Petrovsky, Nikolai
    VACCINE, 2014, 32 (36) : 4651 - 4659
  • [24] Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series
    Cohet, Catherine
    Haguinet, Francois
    Dos Santos, Gael
    Webb, Dave
    Logie, John
    Ferreira, Germano Lc
    Rosillon, Dominique
    Shinde, Vivek
    BMJ OPEN, 2016, 6 (01):
  • [25] Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons
    Jackson, Lisa A.
    Chen, Wilbur H.
    Stapleton, Jack T.
    Dekker, Cornelia L.
    Wald, Anna
    Brady, Rebecca C.
    Edupuganti, Srilatha
    Winokur, Patricia
    Mulligan, Mark J.
    Keyserling, Harry L.
    Kotloff, Karen L.
    Rouphael, Nadine
    Noah, Diana L.
    Hill, Heather
    Wolff, Mark C.
    JOURNAL OF INFECTIOUS DISEASES, 2012, 206 (06) : 811 - 820
  • [26] Guillain-Barre Syndrome after H1N1 Vaccination in the United States: A Report Using the CDC/FDA Vaccine Adverse Event Reporting System (2009)
    Souayah, Nizar
    Yacoub, Hussam A.
    Khan, Hafiz M. R.
    Michas-Martin, P. A.
    Menkes, Daniel L.
    Maybodi, Leila
    Qureshi, Adnan I.
    NEUROEPIDEMIOLOGY, 2012, 38 (04) : 227 - 232
  • [27] Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
    Ikematsu, Hideyuki
    Tenjinbaru, Kazuyoshi
    Li, Ping
    Madan, Anuradha
    Vaughn, David
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (08) : 1119 - 1125
  • [28] Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials
    Roman, Francois
    Clement, Frederic
    Dewe, Walthere
    Walravens, Karl
    Maes, Cathy
    Willekens, Julie
    De Boever, Fien
    Hanon, Emmanuel
    Leroux-Roels, Geert
    CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (05) : 835 - 843
  • [29] Modeling Receipt of Influenza A(H1N1)pdm09 Vaccinations Among US Children During the 2009-2010 Flu Season Findings From the 2010 National Health Interview Survey
    Blackwell, Debra L.
    MEDICAL CARE, 2015, 53 (02) : 191 - 198